Citations

Mayo Clinic

Showing 10 of 108599 citations.

Outcome of very young (≤40 years) patients with immunoglobulin light chain (AL) amyloidosis
Abeykoon, Jithma P. , Dingli, David , Baudi, Francis K., Kyle, Robert A. , Lacy, Martha Q. , Hayman, Suzanne R. , Kourelis, Taxiarchis , Kumar, Shaji , Kapoor, Prashant , Paludo, Jonas , Dispenzieri, Angela , Gertz, Morie A. , Gonsalves, Wilson I. , Leung, Nelson , Rajkumar, S. Vincent , Dingli, David

Amyloid | April 22, 2017 | Volume: 24 | Issue: sup1 | Pages: 50-51

10.1080/13506129.2017.1286584 | PMID 28434368 Get It

Recommendations from the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, 1 April 2016
Maurer, Mathew S. , Lousada, Isabelle , Hanna, Mazen , Ruberg, Frederick L. , Mohty, Dania , Liedtke, Michaela , Paulson, Ingrid , Vest, John, Grogan, Martha , Maurer, Mathew S , Dispenzieri, Angela , Vest, John

Amyloid | April 22, 2017 | Volume: 24 | Issue: sup1 | Pages: 165-166

10.1080/13506129.2017.1286582 | PMID 28434366 Get It

Feasibility study of cardiac magnetic resonance elastography in cardiac amyloidosis
Chang, Ian C , Arani, Arvin , Arunachalam, Shivaram P. , Grogan, Martha , Araoz, Philip A. , Chang, Ian C Y, Poigai Arunachalam, Shivaram, Dispenzieri, Angela , Arunachalam, S P , Arani, Arvin

Amyloid | April 22, 2017 | Volume: 24 | Issue: sup1 | Pages: 161-161

10.1080/13506129.2017.1278689 | PMID 28434361 Get It

Intracranial Dural Arteriovenous Fistulae
Reynolds, Matthew R. , Zipfel, Gregory J. , Lanzino, Giuseppe

Stroke | April 22, 2017 | Volume: 48 | Issue: 5 | Pages: 1424-1431

10.1161/strokeaha.116.012784 | PMID 28432263 Get It

Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder
Asgari, Nasrin , Flanagan, Eoin P. , Kim, Ho Jin , Skejoe, H.P.B., Wuerfel, Jens , Kuroda, Hiroshi , Kim, Su Hyun , Marignier, Romain , Pittock, Sean J. , Paul, Friedemann , Weinshenker, Brian G. , Skejoe, Hanne P, Maillart, Elisabeth, Pittock, S J , Fujihara, Kazuo , Maillart, Elisabeth , Flanagan, E P , Weinshenker, Brian G , Paul, Friedemann

Neurology Neuroimmunology & Neuroinflammation | April 22, 2017 | Volume: 4 | Issue: 4 | Pages: No page available

10.1212/nxi.0000000000000343 | PMID 28451627 Get It

Risks of Deficits after Total Removal of Schwannoma and Resection of Host Root
Kim, Phyo , Takakura, Kintomo, Ebersold, Michael J., Onofrio, Burton M.

Spinal Surgery | April 21, 2017 | Volume: 6 | Pages: 117-121

10.2531/spinalsurg.6.117 Get It

Enhancing Insights into Pulmonary Vascular Disease Through a Precision Medicine Approach. A Joint NHLBI–Cardiovascular Medical Research and Education Fund Workshop Report
Newman, John H. , Rich, Stuart , Alexander, John H. , Beck, Gerald J. , Benza, Raymond L. , Bull, Todd M., Chun, Hyung J. , Doogan, Declan, Dupuis, Jocelyn , Erzurum, Serpil C. , Frantz, Robert P. , Geraci, Mark W. , Gillies, Hunter , Gladwin, Mark T. , Gray, Michael P. , Hill, Nicholas S. , Hunter, Kendall S. , Jing, Zhi‐Cheng , Johns, Roger A. , Kaul, Sanjay , Lahm, Tim , Lewis, Greg , Mathai, Stephen C. , McLaughlin, Vallerie V. , Michelakis, Evangelos D. , Nathan, Steven D. , Nichols, William C. , Page, Grier P. , Rabinovitch, Marlene , Rich, Jonathan D. , Rischard, Franz , Rounds, Sharon , Shah, Sanjiv J. , Tapson, Victor F. , Lowy, Naomi, Stockbridge, Norman, Weinmann, Gail, Xiao, Lei , Xiao, Lei , Abman, Steven H. , Barnard, John , Benza, Raymond L. , Chan, Stephen Y. , Hemnes, Anna R. , Herbst, Roy S. , Hernandez, Adrian F. , Horn, Evelyn M. , Kawut, Steven M. , Leopold, Jane A. , McLaughlin, Vallerie V. , Shah, Sanjiv J , Frantz, Robert P , Rischard, Franz P , Mathai, Stephen C

American Journal of Respiratory and Critical Care Medicine | April 21, 2017 | Volume: 195 | Issue: 12 | Pages: 1661-1670

10.1164/rccm.201701-0150ws | PMID 28430547 Get It

Abstract The Division of Lung Diseases of the NHLBI and the Cardiovascular Medical Education and Research Fund held a workshop to discuss how to leverage the anticipated scientific output from the recently launched “Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics” (PVDOMICS) program to develop newer approaches to pulmonary vascular disease. PVDOMICS is a collaborative, protocol-driven network to analyze all patient populations with pulmonary hypertension to define novel pulmonary vascular disease (PVD) phenotypes. Stakeholders, including basic, translational, and clinical investigators; clinicians; patient advocacy organizations; regulatory agencies; and pharmaceutical industry experts, joined to discuss the application of precision medicine to PVD clinical trials. Recommendations were generated for discussion of research priorities in line with NHLBI Strategic Vision Goals that include: (1) A national effort, involving all the stakeholders, should seek to coordinate biosamples and biodata from all funded programs to a web-based repository so that information can be shared and correlated with other research projects. Example programs sponsored by NHLBI include PVDOMICS, Pulmonary Hypertension Breakthrough Initiative, the National Biological Sample and Data Repository for PAH, and the National Precision Medicine Initiative. (2) A task force to develop a master clinical trials protocol for PVD to apply precision medicine principles to future clinical trials. Specific features include: (a) adoption of smaller clinical trials that incorporate biomarker-guided enrichment strategies, using adaptive and innovative statistical designs; and (b) development of newer endpoints that reflect well-defined and clinically meaningful changes. (3) Development of updated and systematic variables in imaging, hemodynamic, cellular, genomic, and metabolic tests that will help precisely identify individual and shared features of PVD and serve as the basis of novel phenotypes for therapeutic interventions.
Pooled analysis of three randomized, double‐blind, placebo controlled trials with rimonabant for smoking cessation
Robinson, Jason D. , Aubin, Henri‐Jean , Dale, Lowell C., Niaura, Raymond , Anthenelli, Robert M. , Group, the STRATUS, Cinciripini, Paul M , Karam‐Hage, Maher , Group, the STRATUS

Addiction Biology | April 21, 2017 | Volume: 23 | Issue: 1 | Pages: 291-303

10.1111/adb.12508 | PMID 28429843 Get It

AbstractDespite the withdrawal of CB1 antagonists, such as rimonabant, from the market and from active clinical development because of concerns about their side effect profiles, research suggests that the endocannabinoid system may play an important role in modulating nicotine's effects. We report the combined results, using a pooled analysis, of three previously unpublished trials assessing rimonabant as a smoking cessation pharmacotherapy conducted between 2002 and 2004. Smokers (n = 2097) motivated to quit were enrolled in three randomized, double‐blind, placebo‐controlled trials, STRATUS EU, US, and META, which consisted of a 10‐week treatment period with either rimonabant 20 mg (n = 789), 5 mg (n = 518; used in only two of the three studies), or placebo (n = 790), in conjunction with brief counseling. The impact of drug on prolonged abstinence and adverse events was examined at 8 weeks (end‐of‐treatment) and at 48 weeks (available for STRATUS EU and US) after the targeted quit date. Rimonabant 20 mg resulted in significantly higher abstinence at end‐of‐treatment and at 48 weeks post‐targeted quit date compared with placebo, while rimonabant 5 mg and placebo did not differ. Serious AEs did not differ by drug group. The 20 mg rimonabant dose, compared with placebo, produced increased nausea, diarrhea, anxiety symptoms, hyporexia, and vomiting, and decreased headache, constipation, and cough. These results support rimonabant 20 mg as a modestly effective aid for smoking cessation. Although work on CB1 antagonists such as rimonabant has mostly been stopped because of unacceptable adverse events, these results may inform and spur the development of other endocannabinoids for smoking cessation.
Intertrochanteric Osteotomy for Femoral Neck Nonunion: Does “Undercorrection” Result in an Acceptable Rate of Femoral Neck Union?
Shearer, David , Barei, David P. , Nork, Sean E., Yuan, Brandon J.

Journal of Orthopaedic Trauma | April 21, 2017 | Volume: 31 | Issue: 8 | Pages: 420-426

10.1097/bot.0000000000000869 | PMID 28430719 Get It

Objectives: To analyze the radiographic outcomes of intertrochanteric osteotomy for the treatment of femoral neck nonunion with “undercorrection” of the Pauwels angle and relative preservation of the proximal femoral anatomy. Design: Retrospective cohort study. Setting: Level-1 trauma center. Patients: Thirty-two patients with established femoral neck nonunions that had been treated with intertrochanteric osteotomy were retrospectively identified through Current Procedural Terminology codes. Seven patients were treated with 30 degree closing wedge osteotomy and 25 with a 20 degree or smaller osteotomy. Intervention: Valgus-producing intertrochanteric osteotomy with a blade plate. Main Outcome Measurements: Femoral neck and intertrochanteric osteotomy osseous union. Results: Thirty-one of 32 patients (97%) went on to osseous union of the femoral neck and all intertrochanteric osteotomies healed. There was no significant difference in the rate of union of the femoral neck between those patients treated with 30 versus 20 degree or less osteotomies. After osteotomy, the mean Pauwels angle decreased from 71 degrees (range 52–95 degrees) to 47 degrees (range 23–67 degrees) and the mean proximal femoral offset decreased by 11 mm (range 0–23 mm). Seven patients developed radiographic signs of avascular necrosis after osteotomy (22%). Three patients of these patients were converted to total hip arthroplasty (9%). Patients treated with a 30 degree osteotomy were more likely to develop avascular necrosis (67% vs. 12%, P-value = 0.014). Conclusions: Valgus-producing intertrochanteric osteotomy with a smaller degree of correction than has been traditionally described leads to an excellent rate of radiographic union while preserving more of the native proximal femoral anatomy. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
Regulation of vascular large-conductance calcium-activated potassium channels by Nrf2 signalling
Wang, Xiao-Li, Sun, Xiaojing , Chai, Qiang , Thompson, Benjamin , Shen, Win-Kuang, Lü, Tong , Lee, Hon-Chi, Li, Jingchao, Li, Yong , Wang, Xiao-Li, Li, Jingchao , Lu, Tong

Diabetes and Vascular Disease Research | April 21, 2017 | Volume: 14 | Issue: 4 | Pages: 353-362

10.1177/1479164117703903 | PMID 28429615 Get It

BK channels are major ionic determinants of vasodilation. BK channel function is impaired in diabetic vessels due to accelerated proteolysis of its beta-1 (BK-β1) subunits in response to increased oxidative stress. The nuclear factor E2-related factor-2 (Nrf2) signalling pathway has emerged as a master regulator of cellular redox status, and we hypothesized that it plays a central role in regulating BK channel function in diabetic vessels. We found that Nrf2 expression was markedly reduced in db/db diabetic mouse aortas, and this was associated with significant downregulation of BK-β1. In addition, the muscle ring finger protein 1 (MuRF1), a known E-3 ligase targeting BK-β1 ubiquitination and proteasomal degradation, was significantly augmented. These findings were reproduced by knockdown of Nrf2 by siRNA in cultured human coronary artery smooth muscle cells. In contrast, adenoviral transfer of Nrf2 gene in these cells downregulated MuRF1 and upregulated BK-β1 expression. Activation of Nrf2 by dimethyl fumarate preserved BK-β1 expression and protected BK channel and vascular function in db/db coronary arteries. These results indicate that expression of BK-β1 is closely regulated by Nrf2 and vascular BK channel function can be restored by Nrf2 activation. Nrf2 should be considered a novel therapeutic target in the treatment of diabetic vasculopathy.